AUGMENTIN ES 600 MG5 ML

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

AMOXICILLIN AS TRIHYDRATE; CLAVULANIC ACID AS POTASSIUM SALT

متاح من:

GLAXO SMITH KLINE (ISRAEL) LTD

ATC رمز:

J01CR02

الشكل الصيدلاني:

POWDER FOR SUSPENSION

تركيب:

AMOXICILLIN AS TRIHYDRATE 600 MG / 5 ML; CLAVULANIC ACID AS POTASSIUM SALT 42.9 MG / 5 ML

طريقة التعاطي:

PER OS

نوع الوصفة الطبية :

Required

المصنعة من قبل:

GLAXO WELLCOME PRODUCTION, FRANCE

المجال العلاجي:

AMOXICILLIN AND ENZYME INHIBITOR

الخصائص العلاجية:

Augmentin ES is indicated for the treatment of acute otitis media in children aged at least 3 months and less than 40 kg body weight, caused or thought likely to be caused by penicillin-resistant Streptococcus pneumoniae:Consideration should be given to official guidance on the appropriate use of antibacterial agents.

تاريخ الترخيص:

2016-05-31

نشرة المعلومات

( )
"
-
1986
ES
600
" /
5
"
5
"
:
600
(
"
-
)
amoxicillin (as trihydrate)
42.9
(
"
)
clavulanic acid (as potassium salt)
1
:
"
120
(
"
-
)
amoxicillin (as trihydrate)
8.58
)
(
"
clavulanic acid (as potassium salt)
6
.
.
.
,
.
.
.
.
1
.
?
600
ES
"
/
5
"
3
-
40
."
.
.
(
"
"
.
)
(
.)
:
:
-
2
. :
•
,
,
)
(
(
6
)
•
.
•
.
)
(
←
.
,
.
:
,
•
•
•
.
,
.
,
,
.
.
.
,
(
,
.
)
.
,
'
'
4
.
(
,)
(
)
.
. , , , , ,
.
•
(
,
)
.
•
(
,)
.
•
)
(
.
,
•
(
.)
•
(
.) ,
,
.
.
.
.
•
2.72
(
"
E
951
)
1
.
"
,"
"
.
.
•
.)
(
.
,
•
-
23
"
5
.
"
3
.
?
.
.
:
.
40 "
•
40
.
"
.
-
40 "
.
•
.
•
.
.
3
.
•
.
.
•
.
:
(
,
.
)
(
,
:
.
)
•
•
•
,
,
4
.
2
.
•
.
.
,
(
.
.
)
,
.
,
.
,
,
.
,
-
4
.
-
4
.
.
.
.
,
.
. ! .
. ,
.
4
.
,
600
ES
/"
5
"
.
.
.
.
:
:
•
•
(
)
,
•
,
,
,
•
(
,
,)
•
.
•
,
(
-
Kounis syndrome
)
.
←
.
.
,
,
/
.
)
(
(
DIES
)
DIES
/
.
(
1-4
.)
,
)
(
,
.
(
acute pancreatitis
)
.
←
. :
-
1
10
:
•
.)
(
-
1
10
:
•
(
-
)
,
•
,
←
,
•
•
.)
(
-
1
100
:
•
,
•
(
)
•
•
•
.
:
•
.
-
1
1,000
:
•
(
,
,
-
erythema
multiforme
)
←
.
:
•
•
.
( )
•
)
(
•
)
(
•
)
(
(
DIES
)
)
(
•
(
acute pancreatitis
)
)
(
•
(
)
•
:
-
,
,
,
(
-
'
,
,)
(
-
30%
-
)
-
(
bullous exfoliative dermatitis
)
-
,
(
exanthematous pustulosis
)
-
,
,
,
)
]
[
(
[
(
DRESS
.)]
-
(
IgA
)
←
.
•
(
)
•
(
,
)
•
•
•
)
(
•
)
(
•
•
.
,)
(
:
•
•
(
)
•
. , . ,
"
"
(
www.health.gov.il
"
,
)
:
https://sideeffects.health.gov.il/
5
.
?
•
!
.
/
.
•
(
exp. date
)
.
. :
•
25°C
.
•
.
:
•
(
2°C
8°C
.
.)
•
,
10
.
•
.
.
.
6
.
•
:
Silicon dioxide, colloidal anhydrous silica, carboxymethyl cellulose
sodium,
artificial strawberry cream flavour (including maltodextrine),
aspartame
(E951) and xanthan gum.
'
'
2
.
•
:
.
ES
600
/"
5
"
,
.
100
"
.
•
' ,"
)
(
:
25
. ,
•
:
. ,
,
,
,
'
.
•
2023
.
•
:
145-87-33332
.
•
,
.
,
.
•
GSK
.
2023©
GSK
. :
.
.
.
1
.
.
2
.
.
3
.
.
4
.
100
"
90
"
.
,
.
AugES PT v10B

خصائص المنتج

1
Augmentin ES 600 mg/5 ml
1.
NAME OF THE MEDICINAL PRODUCT
Augmentin ES 600 mg/5 ml
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
When reconstituted, every ml of oral suspension contains amoxicillin
trihydrate equivalent to 120 mg
amoxicillin and potassium clavulanate equivalent to 8.58 mg of
clavulanic acid.
Excipient with known effect
Every ml of oral suspension contains 2.72 mg aspartame (E951). The
flavouring in Augmentin ES 600 mg/5
ml contains maltodextrin (glucose) (see section 4.4).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for oral suspension.
Off-white powder.
4.
CLINICAL PARTICULARS
4.1
Therapeutic indications
Augmentin
_ES_
600 mg/5 ml is indicated for the treatment of acute otitis media in
children aged at least 3
months and less than 40 kg body weight, caused or thought likely to be
caused by penicillin-resistant
_Streptococcus pneumoniae_
(see sections 4.2, 4.4 and 5.1).
Consideration should be given to official guidance on the appropriate
use of antibacterial agents.
4.2
Posology and method of administration
Posology
Doses are expressed throughout in terms of amoxicillin/clavulanic acid
content except when doses are stated
in terms of an individual component.
The dose of Augmentin
_ES_
600 mg/5 ml that is selected to treat an individual infection should
take into account:
•
The expected pathogens and their likely susceptibility to
antibacterial agents (see section 4.4)
•
The severity and the site of the infection
•
The age, weight and renal function of the patient as shown below.
Treatment should not be extended beyond 14 days without review (see
section 4.4 regarding prolonged
therapy).
Adults and children
≥
40 kg:
There is no experience with Augmentin ES 600 mg/5 ml suspension in
adults and children
≥
40 kg, and
therefore no dose recommendation can be given.
2
Children < 40 kg (aged
≥
3 months)
The recommended dose of Augmentin
_ES_
600 mg/5 ml suspension is 90/6.4 mg/kg/day in two divided doses.
There are no clinical data on Augmentin
_ES_
600 mg